GenMark Diagnostics Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Akero Therapeutics Inc (...

Coronavirus test maker GenMark Diagnostics soared to a record high after second-quarter sales shattered expectations. GenMark has quadrupled in 2020 in the face of the Covid-19 pandemic.

Shares of GenMark Diagnostics (NASDAQ: GNMK) were soaring 21.6% as of 11:44 a.m. EDT on Wednesday. The big jump came after GenMark provided preliminary second-quarter results Tuesday evening. It's e

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) * AbbVie Inc (NYSE: ABBV) * ACADIA Pharmaceuticals In

Shares in GenMark Diagnostics (GNMK) are soaring 10% in Wednesday’s pre-market trading after the molecular diagnostics company announced impressive preliminary financial and operational results for

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV)...

GenMark Diagnostics, Inc. (GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary financial and operational results for the quarter ended Ju

GenMark Diagnostics, Inc (NASDAQ:GNMK) SVP Brian Andrew Mitchell sold 4,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $14.45,

Stocks Analysis by Harry Boxer covering: Crocs Inc, Tesla Inc, Celldex Therapeutics Inc, GenMark Diagnostics Inc. Read Harry Boxer's latest article on Investing.com

GenMark Diagnostics, Inc. (GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that its ePlex® Respiratory Pathogen 2 (RP2) Panel is now available for U.

The

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of Ma

This strategy isn’t just a winner, these analysts think, but evidence that hedge funds may finally start to out-perform.

This strategy isn’t just a winner, these analysts think, but evidence that hedge funds may finally start to out-perform.

The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (...